SCHEMBL1241585

SCHEMBL1241585

CC(C)(C)c1ccc(CN(C(=O)C(=O)O)c2ccc(Cl)c(-c3ccc(OC(F)(F)F)cc3)c2)cc1

nearest known ligand 0.59

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
SERPINE1 P05121 12/20 0.59
GCGR P47871 2/20 0.47
GIPR P48546 2/20 0.47
GLP1R P43220 1/20 0.47
FFAR4 Q5NUL3 3/20 0.45
FFAR1 O14842 2/20 0.45
CYP2C9 P11712 1/20 0.45
SCN5A Q14524 1/20 0.45
NR1H4 Q96RI1 2/20 0.43
EPHX2 P34913 1/20 0.43
PTGES O14684 1/20 0.40
ALOX5 P09917 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1239762 0.91 SERPINE1 (0.47) SERPINE1GCGRGIPRGLP1RFFAR4
SCHEMBL1241748 0.90 SERPINE1 (0.60) SERPINE1GCGRGIPRGLP1RNR1H4
SCHEMBL1241726 0.88 SERPINE1 (0.58) SERPINE1GCGRGIPRGLP1RNR1H4
SCHEMBL1241763 0.88 SERPINE1 (0.60) SERPINE1GCGRGIPRGLP1RNR1H4
SCHEMBL1241449 0.87 SERPINE1 (0.77) SERPINE1GCGRGIPRGLP1RNR1H4
SCHEMBL1241549 0.87 SERPINE1 (0.77) SERPINE1GCGRGIPRGLP1RNR1H4
SCHEMBL1242259 0.87 SERPINE1 (0.60) SERPINE1GCGRGIPRGLP1RNR1H4
SCHEMBL1239876 0.86 SERPINE1 (0.56) SERPINE1GCGRGIPRGLP1RCYP2C9
SCHEMBL1242179 0.86 SERPINE1 (0.75) SERPINE1GCGRGIPRGLP1RNR1H4
SCHEMBL1239773 0.85 SERPINE1 (0.55) SERPINE1GCGRGIPRGLP1RFFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7884234-B2 N-[4-(tert-butyl)benzyl]-N-[4 -(trifluoromethoxy)biphenyl-3-yl]oxamic Acid; Inhibitors of plasminogen activator inhibitor-1 (PAI-1); thrombogenesis, fibrogenesis, accumulation of visceral fat, cell proliferation, angiogenesis INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2011-02-08 US disclosed
US-20090215899-A9 N-Phenyloxamide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-08-27 US disclosed
EP-2072498-A1 N-PHENYLOXAMIDIC ACID DERIVATIVE Institute of Medicinal Molecular Design, Inc. (JP) 2009-06-24 EP disclosed
US-20080249175-A1 N-Phenyloxamide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2008-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080249175-A1 N-Phenyloxamide derivatives SERPINE1, SERPINH1, F12 SERPINE1 1/4885GCGR 1724/4885GIPR 2082/4885
US-20090215899-A9 N-Phenyloxamide derivatives SERPINE1, SERPINH1, F12 SERPINE1 1/4885GCGR 1724/4885GIPR 2082/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.